US FDA Coronavirus Response Features Three-Step Triage Process For Inquiries

Office of New Drugs Director Peter Stein outlines how his reviewers are prioritizing COVID-19 work, and how he is reallocating resources to the pandemic response.

COVID-19 SARS,Coronaviridae , SARS-CoV, SARSCoV, virus 2020 , MERS-CoV ,chinese virus 2019-nCoV

The US Food & Drug Administration is triaging COVID-19 treatment protocols and other coronavirus-related inquiries coming into the agency using a team led by the Division of Anti-Infectives as part of an unprecedented reallocation of personnel across the agency in response to the pandemic, Office of New Drugs Director Peter Stein said in an interview with the Pink Sheet.

The group, known as the “COVID Scientific Technical Triage Team,” is the forward-facing part of the Coronavirus Treatment Acceleration Program,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.